Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pancreas. 2010 Oct;39(7):989-93. doi: 10.1097/MPA.0b013e3181d91936.

Impact of S-1 on the survival of patients with advanced pancreatic cancer.

Author information

  • 1Department of Gastroenterology, University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Abstract

OBJECTIVE:

The aim of this study was to investigate the effect of S-1 on the prognosis of advanced pancreatic cancer.

METHODS:

In total, 112 patients with pancreatic cancer who received chemotherapy between April 2001 and April 2007 were divided into 2 groups: PreS-1 (53 patients who started chemotherapy before January 2005) and PostS-1 (59 patients who started chemotherapy after February 2005, the time of S-1 introduction). Patient characteristics and clinical outcomes were compared, and prognostic factors were analyzed.

RESULTS:

Patient characteristics did not significantly differ between the 2 groups. S-1 was administered as a second-line monotherapy in 5.7% of the PreS-1 group and combined with gemcitabine as a first-line therapy in 27.1% or as second-line monotherapy in 23.7% in the PostS-1 group. Both progression-free survival and overall survival improved after introduction of S-1 (median progression-free survival, 4.4 and 5.3 months; P = 0.043; median overall survival, 9.5 and 13.1 months; P = 0.048 in PreS-1 and PostS-1 groups, respectively). Multivariate analysis revealed that the PostS-1 group (hazards ratio, 0.52; P = 0.003), performance status, and carcinoembryonic antigen were significant prognostic factors for survival.

CONCLUSIONS:

Introduction of S-1 may improve the prognosis of Japanese patients with advanced pancreatic cancer.

PMID:
20467352
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk